UPDATE 1-Novo Nordisk's obesity drug falls short against Eli Lilly's in trial
Eli Lilly and Company 0.00% Pre
Eli Lilly and Company LLY | 905.03 911.00 | 0.00% +0.66% Pre |
Adds share reaction in paragraph 2, detail in paragraph 3
COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk NOVOb.CO said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing body weight.
Novo Nordisk's share price fell 8% by 0946 GMT.
Novo Nordisk said CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for Eli Lilly's tirzepatide in the trial.
